Cargando…

(68)Ga-labelled desferrioxamine-B for bacterial infection imaging

PURPOSE: With the increase of especially hospital-acquired infections, timely and accurate diagnosis of bacterial infections is crucial for effective patient care. Molecular imaging has the potential for specific and sensitive detection of infections. Siderophores are iron-specific chelators recogni...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrik, Milos, Umlaufova, Eva, Raclavsky, Vladislav, Palyzova, Andrea, Havlicek, Vladimir, Pfister, Joachim, Mair, Christian, Novy, Zbynek, Popper, Miroslav, Hajduch, Marian, Decristoforo, Clemens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835195/
https://www.ncbi.nlm.nih.gov/pubmed/32734456
http://dx.doi.org/10.1007/s00259-020-04948-y
Descripción
Sumario:PURPOSE: With the increase of especially hospital-acquired infections, timely and accurate diagnosis of bacterial infections is crucial for effective patient care. Molecular imaging has the potential for specific and sensitive detection of infections. Siderophores are iron-specific chelators recognized by specific bacterial transporters, representing one of few fundamental differences between bacterial and mammalian cells. Replacing iron by gallium-68 without loss of bioactivity is possible allowing molecular imaging by positron emission tomography (PET). Here, we report on the preclinical evaluation of the clinically used siderophore, desferrioxamine-B (Desferal®, DFO-B), radiolabelled with (68)Ga for imaging of bacterial infections. METHODS: In vitro characterization of [(68)Ga]Ga-DFO-B included partition coefficient, protein binding and stability determination. Specific uptake of [(68)Ga]Ga-DFO-B was tested in vitro in different microbial cultures. In vivo biodistribution was studied in healthy mice and dosimetric estimation for human setting performed. PET/CT imaging was carried out in animal infection models, representing the most common pathogens. RESULTS: DFO-B was labelled with (68)Ga with high radiochemical purity and displayed hydrophilic properties, low protein binding and high stability in human serum and PBS. The high in vitro uptake of [(68)Ga]Ga-DFO-B in selected strains of Pseudomonas aeruginosa, Staphylococcus aureus and Streptococcus agalactiae could be blocked with an excess of iron-DFO-B. [(68)Ga]Ga-DFO-B showed rapid renal excretion and minimal retention in blood and other organs in healthy mice. Estimated human absorbed dose was 0.02 mSv/MBq. PET/CT images of animal infection models displayed high and specific accumulation of [(68)Ga]Ga-DFO-B in both P. aeruginosa and S. aureus infections with excellent image contrast. No uptake was found in sterile inflammation, heat-inactivated P. aeruginosa or S. aureus and Escherichia coli lacking DFO-B transporters. CONCLUSION: DFO-B can be easily radiolabelled with (68)Ga and displayed suitable in vitro characteristics and excellent pharmacokinetics in mice. The high and specific uptake of [(68)Ga]Ga-DFO-B by P. aeruginosa and S. aureus was confirmed both in vitro and in vivo, proving the potential of [(68)Ga]Ga-DFO-B for specific imaging of bacterial infections. As DFO-B is used in clinic for many years and the estimated radiation dose is lower than for other (68)Ga-labelled radiopharmaceuticals, we believe that [(68)Ga]Ga-DFO-B has a great potential for clinical translation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-020-04948-y) contains supplementary material, which is available to authorized users.